Please assess the completion status of the following clinical trial:

Trial Title: A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult participants, ≥ 18 years of age.~* Locally advanced or recurrent (stage IIIB) or metastatic (stage IV) non-small cell lung cancer.~* Presence of epidermal growth factor receptor (EGFR) mutations in tumours.~* Measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 criteria.~* European Cooperative Oncology Group (ECOG) performance status ≤ 2.~Exclusion Criteria:~* Prior exposure to agents directed at the human epidermal receptor (HER) axis (eg, but not limited to erlotinib, gefitinib, cetuximab, or trastuzumab).~* Prior chemotherapy or systemic anti-neoplastic therapy for advanced disease.~* Lack of physical integrity of the upper gastrointestinal tract, or malabsorption syndrome, or inability to take oral medication, or active gastroduodenal ulcer disease.~* Any inflammatory changes of the surface of the eye.~* ≥ Grade 2 peripheral neuropathy.~* History of any other malignancies within 5 years, except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer.~* Brain metastasis or spinal cord compression that has not yet been definitely treated with surgery and/or radiation, or treated but without evidence of stable disease for at least 2 months.~* Human immunodeficiency virus (HIV) infection.~* Pregnant, nursing, or lactating women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Erlotinib (Type: EXPERIMENTAL): Participants received erlotinib 150 mg orally once daily until progressive disease or unacceptable toxicity.
- Chemotherapy (Type: ACTIVE_COMPARATOR): Participants received gemcitabine 1250 mg/m\^2 intravenously (IV) on Days 1 and 8 and cisplatin 75 mg/m\^2 IV on Day 1 of every 3 week cycle until disease progression, unacceptable toxicity, or a total of 4 cycles, whichever came first.

Based on this trial design, predict the completion outcome and termination type (if applicable).